PL3211005T3 - Terapeutyczne zastosowanie specyficznego liganda w chorobach związanych z MSRV - Google Patents

Terapeutyczne zastosowanie specyficznego liganda w chorobach związanych z MSRV

Info

Publication number
PL3211005T3
PL3211005T3 PL17159699T PL17159699T PL3211005T3 PL 3211005 T3 PL3211005 T3 PL 3211005T3 PL 17159699 T PL17159699 T PL 17159699T PL 17159699 T PL17159699 T PL 17159699T PL 3211005 T3 PL3211005 T3 PL 3211005T3
Authority
PL
Poland
Prior art keywords
therapeutic use
associated diseases
specific ligand
msrv
msrv associated
Prior art date
Application number
PL17159699T
Other languages
English (en)
Inventor
Corinne Bernard
Alois Bernhardt Lang
Hervé Perron
Jean-Baptiste Bertrand
Original Assignee
Geneuro Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro Sa filed Critical Geneuro Sa
Publication of PL3211005T3 publication Critical patent/PL3211005T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
PL17159699T 2008-07-08 2009-07-08 Terapeutyczne zastosowanie specyficznego liganda w chorobach związanych z MSRV PL3211005T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US12961308P 2008-07-08 2008-07-08
US20258109P 2009-03-13 2009-03-13
US21318909P 2009-05-15 2009-05-15
PCT/EP2009/058663 WO2010003977A1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases
EP17159699.2A EP3211005B1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases
EP09780311.8A EP2315777B1 (en) 2008-07-08 2009-07-08 Therapeutic use of specific ligand in msrv associated diseases

Publications (1)

Publication Number Publication Date
PL3211005T3 true PL3211005T3 (pl) 2021-11-29

Family

ID=41165692

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17159699T PL3211005T3 (pl) 2008-07-08 2009-07-08 Terapeutyczne zastosowanie specyficznego liganda w chorobach związanych z MSRV
PL09780311T PL2315777T3 (pl) 2008-07-08 2009-07-08 Terapeutyczne zastosowanie specyficznego liganda w chorobach powiązanych z msrv

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09780311T PL2315777T3 (pl) 2008-07-08 2009-07-08 Terapeutyczne zastosowanie specyficznego liganda w chorobach powiązanych z msrv

Country Status (24)

Country Link
US (4) US8715656B2 (pl)
EP (2) EP2315777B1 (pl)
JP (3) JP6058264B2 (pl)
KR (1) KR101682040B1 (pl)
CN (1) CN102143975B (pl)
AU (1) AU2009268025B2 (pl)
BR (1) BRPI0915667B8 (pl)
CA (1) CA2729869C (pl)
CY (2) CY1119185T1 (pl)
DK (1) DK3211005T3 (pl)
EA (1) EA024655B1 (pl)
ES (2) ES2633965T3 (pl)
HR (2) HRP20171067T1 (pl)
HU (2) HUE033803T2 (pl)
IL (1) IL210204A (pl)
LT (2) LT2315777T (pl)
MX (1) MX2010014319A (pl)
NZ (1) NZ590515A (pl)
PL (2) PL3211005T3 (pl)
PT (2) PT2315777T (pl)
SI (2) SI3211005T1 (pl)
SM (1) SMT201700366T1 (pl)
WO (1) WO2010003977A1 (pl)
ZA (1) ZA201100446B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174053A1 (en) 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
SMT201700366T1 (it) * 2008-07-08 2017-09-07 Geneuro Sa Uso terapeutico di ligando specifico in malattie associate a msrv
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
EP2949342A1 (en) * 2014-05-28 2015-12-02 Geneuro SA Antiretroviral drug targeting human endogenous retrovirus
EP3367786A1 (en) * 2015-10-29 2018-09-05 H. Hoffnabb-La Roche Ag Transgenic rabbit with common light chain
JP2018028538A (ja) * 2016-08-12 2018-02-22 公立大学法人名古屋市立大学 統合失調症とその関連疾患の診断用マーカー及びその使用
WO2019201908A1 (en) 2018-04-17 2019-10-24 Geneuro Sa Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein
EP3916015A1 (en) * 2020-05-28 2021-12-01 Geneuro SA Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
CN113940993B (zh) * 2021-12-20 2022-02-22 深圳万可森生物科技有限公司 一种鲈鱼弹状病毒g2-2m亚单位疫苗及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPH05501352A (ja) 1989-08-09 1993-03-18 ディカルブ　ジェネティクス　コーポレイション 安定な形質転換稔性単子葉植物およびそれらの細胞を製造するための方法および組成物
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7473423B2 (en) * 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
FR2734842B1 (fr) 1995-06-02 1998-02-27 Rhone Poulenc Agrochimie Sequence adn d'un gene de l'hydroxy-phenyl pyruvate dioxygenase et obtention de plantes contenant un gene de l'hydroxy-phenyl pyruvate dioxygenase, tolerantes a certains herbicides
FR2736926B1 (fr) 1995-07-19 1997-08-22 Rhone Poulenc Agrochimie 5-enol pyruvylshikimate-3-phosphate synthase mutee, gene codant pour cette proteine et plantes transformees contenant ce gene
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
WO2004106383A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
PL1674111T3 (pl) 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
AU2005280975B2 (en) 2004-09-06 2009-06-18 Kyowa Hakko Kirin Co., Ltd. Anti-A33 antibody
EP2208783A1 (en) * 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2006137354A1 (ja) 2005-06-21 2006-12-28 Medical & Biological Laboratories Co., Ltd. アミロイド線維形成に対する阻害活性を有する抗体
FR2912314B1 (fr) 2007-02-09 2012-08-03 Geneuro Sa Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
SMT201700366T1 (it) * 2008-07-08 2017-09-07 Geneuro Sa Uso terapeutico di ligando specifico in malattie associate a msrv

Also Published As

Publication number Publication date
KR20110031969A (ko) 2011-03-29
JP6058264B2 (ja) 2017-01-11
IL210204A0 (en) 2011-03-31
JP6495361B2 (ja) 2019-04-03
IL210204A (en) 2015-03-31
HK1243436A1 (en) 2018-07-13
US8715656B2 (en) 2014-05-06
SI3211005T1 (sl) 2021-06-30
AU2009268025B2 (en) 2014-07-31
HRP20210892T1 (hr) 2021-11-26
ES2875762T3 (es) 2021-11-11
HK1158232A1 (en) 2012-07-13
CY1119185T1 (el) 2018-02-14
EA201100160A1 (ru) 2011-08-30
AU2009268025A1 (en) 2010-01-14
CN102143975A (zh) 2011-08-03
EP3211005B1 (en) 2021-03-17
BRPI0915667A2 (pt) 2017-01-17
US9550824B2 (en) 2017-01-24
EP2315777B1 (en) 2017-04-26
US9815888B2 (en) 2017-11-14
LT2315777T (lt) 2017-10-25
ES2633965T3 (es) 2017-09-26
WO2010003977A1 (en) 2010-01-14
MX2010014319A (es) 2011-05-19
PT2315777T (pt) 2017-07-25
EA024655B1 (ru) 2016-10-31
US20140220026A1 (en) 2014-08-07
JP2015157812A (ja) 2015-09-03
DK3211005T3 (da) 2021-06-07
CN102143975B (zh) 2014-12-31
NZ590515A (en) 2013-01-25
CA2729869A1 (en) 2010-01-14
SMT201700366T1 (it) 2017-09-07
US20180057569A1 (en) 2018-03-01
PL2315777T3 (pl) 2017-10-31
JP6109869B2 (ja) 2017-04-05
US10059758B2 (en) 2018-08-28
ZA201100446B (en) 2012-01-25
SI2315777T1 (sl) 2017-09-29
HUE054712T2 (hu) 2021-09-28
CA2729869C (en) 2018-02-13
JP2011527887A (ja) 2011-11-10
BRPI0915667B8 (pt) 2021-05-25
EP2315777A1 (en) 2011-05-04
CY1124281T1 (el) 2022-07-22
JP2017158550A (ja) 2017-09-14
PT3211005T (pt) 2021-06-15
HUE033803T2 (en) 2018-01-29
BRPI0915667B1 (pt) 2020-10-13
US20110243962A1 (en) 2011-10-06
KR101682040B1 (ko) 2016-12-02
US20170107274A1 (en) 2017-04-20
HRP20171067T1 (hr) 2017-10-06
LT3211005T (lt) 2021-08-25
EP3211005A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
IL249941A0 (en) Spiro-oxaindole substances and medical preparations containing them
ZA201100446B (en) Therapeutic use of specific ligand in msrv associated diseases
GB0803018D0 (en) Therapeutic compounds and their use
GB0804685D0 (en) Therapeutic compounds and their use
GB0817207D0 (en) therapeutic apsac compounds and their use
SI2205245T1 (sl) Terapevtska uporaba diaminofenotiazinov
GB0817208D0 (en) Therapeutic apsap compounds and their use
GB0807609D0 (en) Therapeutic compounds and their use
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0812913D0 (en) Therapeutic compounds and their use
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
GB0802128D0 (en) Therapeutic compounds and their use
GB0821539D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use
GB0819854D0 (en) Therapeutic use of zolpidem
GB0809936D0 (en) Therapeutic use of zolpidem
GB0913300D0 (en) Therapeutic compounds and their use
GB0800489D0 (en) Therapeutic use
GB0800487D0 (en) Therapeutic use
GB0817739D0 (en) New therapeutic use
GB0817740D0 (en) New therapeutic use
GB0804454D0 (en) New therapeutic use
GB0817738D0 (en) New therapeutic use
GB0816979D0 (en) New therapeutic use
GB0817737D0 (en) New therapeutic use